Janus kinase and calcineurin‐inhibitor combination in anti‐MDA5 dermatomyositis: No significant survival benefit but reassuring safety profile
Journal of Internal Medicine · 2026-02 · 299 (2) · 228-240
DOI: 10.1111/joim.70047 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Internal Medicine, online erschienen am 24.11.2025. Verfasst von Valentine Pagis und 47 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Pitié-Salpêtrière University Hospital, AP-HP, Sorbonne University, Paris, France. Hauptthemen laut MEDLINE: Dermatomyositis, Calcineurin Inhibitors, Janus Kinase Inhibitors, Interferon-Induced Helicase, IFIH1. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objectives
Anti‐MDA5 dermatomyositis (anti‐MDA5 DM) is the most severe subtype of dermatomyositis, due to its pulmonary involvement. Current treatment involves corticosteroids and immunosuppressants, but variability in responses exists. This study aims to evaluate the efficacy and safety of Janus kinase (JAK)– and calcineurin–inhibitor combination (JAK–CNI) in anti‐MDA5 DM patients.
Methods
A nested case–control study was conducted within a retrospective cohort of 234 anti‐MDA5 DM patients. Patients receiving JAK–CNI were matched 1:2 with comparators. All‐cause mortality or transplant within a year was compared using Cox proportional hazards models. Infectious and noninfectious side effects were also assessed.
Results
Twenty‐seven patients receiving JAK–CNI were compared to 52 matched controls. Almost all these patients had pulmonary involvement. Thirty‐nine (49%) died or were transplanted during follow‐up. No significant improvement in survival or transplant‐free survival was observed with JAK–CNI compared with comparators (hazard ratios 1.02, 95% confidence intervals [0.48–2.16]). Results were consistent regardless of intensive care unit (ICU) admission status and when analyses were restricted to patients with rapidly progressive interstitial lung disease. A trend toward a beneficial effect of the JAK–CNI combination was observed in non‐ICU patients. Infectious complications were frequent ( n = 49, 62%), with no excess risk in patients receiving JAK–CNI.
Conclusion
JAK–CNI showed a similar outcome to other immunosuppressive combinations. However, as the study included the most severe cases, the potential benefit of early JAK–CNI introduction in less severe forms cannot be dismissed, as suggested by the nonsignificant trend in non‐ICU patients. Future studies are needed to clarify the optimal timing and patient selection for JAK–CNI therapy in anti‐MDA5 DM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Pitié-Salpêtrière University Hospital, AP-HP, Sorbonne University, Paris, France.
- Department of Internal Medicine, Centre de Référence des Maladies Autoimmunes Systémiques Rares du Nord, Nord-Ouest et Méditerranée (CeRAINOM), U1286 - INFINITE-Institute for Translational Research in Inflammation, Univ…
- Department of Internal Medicine, Bicêtre Hospital, AP-HP, Paris-Saclay University, Le Kremlin-Bicêtre, France.
- Department of Internal Medicine, Beaujon Hospital, AP-HP, Paris Cité University, Paris, France.
- Department of Intensive Care Unit, Mondor Hospital, AP-HP, Créteil University, Créteil, France.
- INSERM U955, Team "Viruses, Hepatology, Cancer", Créteil, France.
ORCID-Profile: Valentine Pagis, Quentin Astouati, Lucas Pacoureau, Yann Nguyen, Pierre Bay, Benjamin Terrier, Mathilde Neuville, Baptiste Hervier, Arthur Renaud, Benoit Suzon, Nicolas Schleinitz, Thomas Papo, Pascaline Priou, Arsène Mekinian, Audrey Ullmer, Noémie Gensous, Alice Berezne, Thierry Marhadour, Mickaël Martin, Amélie Servettaz, Maxime Samson, Laurent Gilardin, Pierre Charles, Thierry Carmoi, Baptiste Dilly, Wladimir Mauhin, Sébastien Humbert, Benjamin Thoreau, Marine Lemaitre, Pierre Loiseau, Thomas Quemeneur, Nicol Voermans, David Launay, Hilario Nunes, Olivier Benveniste, Yurdagul Uzunhan, Yves Allenbach
Zitieren
APA
Pagis, V., Astouati, Q., Pacoureau, L., Nguyen, Y., Bay, P., Roux, A., Gallay, L., Cottin, V., Terrier, B., Meyer, A., Cerf, C., Neuville, M., Hervier, B., Renaud, A., Suzon, B., Schleinitz, N., Papo, T., Priou, P., Mekinian, A., …, & Allenbach, Y. (2026). Janus kinase and calcineurin‐inhibitor combination in anti‐MDA5 dermatomyositis: No significant survival benefit but reassuring safety profile. Journal of Internal Medicine, 299(2), 228-240. https://doi.org/10.1111/joim.70047
Vancouver
Pagis V, Astouati Q, Pacoureau L, Nguyen Y, Bay P, Roux A, et al. Janus kinase and calcineurin‐inhibitor combination in anti‐MDA5 dermatomyositis: No significant survival benefit but reassuring safety profile. Journal of Internal Medicine. 2026;299(2):228-240. doi:10.1111/joim.70047
BibTeX
@article{Pagis2026,
author = {Pagis, Valentine and Astouati, Quentin and Pacoureau, Lucas and Nguyen, Yann and Bay, Pierre and Roux, Antoine and Gallay, Laure and Cottin, Vincent and Terrier, Benjamin and Meyer, Alain and Cerf, Charles and Neuville, Mathilde and Hervier, Baptiste and Renaud, Arthur and Suzon, Benoit and Schleinitz, Nicolas and Papo, Thomas and Priou, Pascaline and Mekinian, Arsène and Ullmer, Audrey and Oehler, Erwan and Gensous, Noémie and Berezne, Alice and Martin, Luc De Saint and Marhadour, Thierry and Martin, Mickaël and Servettaz, Amélie and Samson, Maxime and Gilardin, Laurent and Charles, Pierre and Woessner, Juliette and Carmoi, Thierry and Dilly, Baptiste and Mauhin, Wladimir and Baillet, Nicolas and Humbert, Sébastien and Thoreau, Benjamin and Lemaitre, Marine and Pendu, Claire Le and Loiseau, Pierre and Quemeneur, Thomas and Blanchard, Elodie and Voermans, Nicol and Launay, David and Nunes, Hilario and Benveniste, Olivier and Uzunhan, Yurdagul and Allenbach, Yves},
title = {Janus kinase and calcineurin‐inhibitor combination in anti‐MDA5 dermatomyositis: No significant survival benefit but reassuring safety profile},
journal = {Journal of Internal Medicine},
year = {2026},
volume = {299},
number = {2},
pages = {228--240},
doi = {10.1111/joim.70047}
}
EUVIMED